Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF

Open access

Abstract

Rationale: α v integrins, key regulators of transforming growth factor-β activation and fibrogenesis in in vivo models of pulmonary fibrosis, are expressed on abnormal epithelial cells (α v β 6) and fibroblasts (α v β 1) in fibrotic lungs. Objectives: We evaluated multiple α v integrin inhibition strategies to assess which most effectively reduced fibrogenesis in explanted lung tissue from patients with idiopathic pulmonary fibrosis. Methods: Selective α v β 6 and α v β 1, dual α v β 6/α v β 1, and multi-α v integrin inhibitors were characterized for potency, selectivity, and functional activity by ligand binding, cell adhesion, and transforming growth factor-β cell activation assays. Precision-cut lung slices generated from lung explants from patients with idiopathic pulmonary fibrosis or bleomycin-challenged mouse lungs were treated with integrin inhibitors or standard-of-care drugs (nintedanib or pirfenidone) and analyzed for changes in fibrotic gene expression or TGF-β signaling. Bleomycin-challenged mice treated with dual α v β 6/α v β 1 integrin inhibitor, PLN-74809, were assessed for changes in pulmonary collagen deposition and Smad3 phosphorylation. Measurements and main results: Inhibition of integrins α v β 6 and α v β 1 was additive in reducing type I collagen gene expression in explanted lung tissue slices from patients with idiopathic pulmonary fibrosis. These data were replicated in fibrotic mouse lung tissue, with no added benefit observed from inhibition of additional α v integrins. Antifibrotic efficacy of dual α v β 6/α v β 1 integrin inhibitor PLN-74809 was confirmed in vivo, where dose-dependent inhibition of pulmonary Smad3 phosphorylation and collagen deposition was observed. PLN-74809 also, more potently, reduced collagen gene expression in fibrotic human and mouse lung slices than clinically relevant concentrations of nintedanib or pirfenidone. Conclusions: In the fibrotic lung, dual inhibition of integrins α v β 6 and α v β 1 offers the optimal approach for blocking fibrogenesis resulting from integrin-mediated activation of transforming growth factor-β.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12931-021-01863-0

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Effect of αvβ1-selective inhibition (Compound A), αvβ6-selective inhibition (3G9), and dual αvβ6/αvβ1 inhibition (PLN-74809 or Compound A + 3G9) on A COL1A1 mRNA expression and B expression of additional fibrosis-related genes following 7-day culture of PCLSs prepared from lung explants from patients with IPF. Data represent mean (± SD) of 4–5 independent IPF tissues with ≥ 3 slices analyzed per patient tissue. Each symbol within a group represents an individual patient lung, with treatment effects normalized to vehicle. Data in A and B were generated from the same samples. Compound A = 471 nM; 3G9 = 0.5 µg/ml; PLN-74809 = 1.82 µM; TGF-β type I receptor inhibitor (ALK5i [R 268712]) = 1 µM. ALK5i was used as a positive control to confirm TGF-β-driven collagen expression within lung slices. Concentrations selected for integrin inhibitors were ≥ 10 × IC50, determined to inhibit latent TGF-β activation by αvβ1 or αvβ6 in cell-based assays (see Table 1). **P < 0.01 vs DMSO; ****P < 0.0001 vs DMSO. ACTA2: α-smooth muscle actin 2; ALK5i: Activin receptor-like kinase 5 inhibitor; COL1A1: Collagen type I alpha I; COL1A2: Collagen type I alpha II; COL3A1: Collagen type III alpha I; Cpd A: Compound A; CTGF: Connective tissue growth factor; DMSO: Dimethyl sulfoxide; GUSB: Glucuronidase β; IC50: 50% inhibitory concentration; HPRT1: Hypoxanthine phosphoribosyltransferase 1; IPF: Idiopathic pulmonary fibrosis; ITGB6: Integrin subunit β 6; MMP1: Matrix metalloproteinase 1; MMP2: Matrix metalloproteinase 2; MMP7: Matrix metalloproteinase 7; mRNA: Messenger ribonucleic acid; PCLS: Precision-cut lung slice; RPLP0: Ribosomal lateral stalk subunit P0; SD: Standard deviation; SERPINE1: Serpin family E member 1; SNAI1: Snail family transcriptional repressor 1; TGF-β: Transforming growth factor-β; TIMP1: Tissue inhibitor of metalloproteinase 1
Fig. 1 Effect of αvβ1-selective inhibition (Compound A), αvβ6-selective inhibition (3G9), and dual αvβ6/αvβ1 inhibition (PLN-74809 or Compound A + 3G9) on A COL1A1 mRNA expression and B expression of additional fibrosis-related genes following 7-day culture of PCLSs prepared from lung explants from patients with IPF. Data represent mean (± SD) of 4–5 independent IPF tissues with ≥ 3 slices analyzed per patient tissue. Each symbol within a group represents an individual patient lung, with treatment effects normalized to vehicle. Data in A and B were generated from the same samples. Compound A = 471 nM; 3G9 = 0.5 µg/ml; PLN-74809 = 1.82 µM; TGF-β type I receptor inhibitor (ALK5i [R 268712]) = 1 µM. ALK5i was used as a positive control to confirm TGF-β-driven collagen expression within lung slices. Concentrations selected for integrin inhibitors were ≥ 10 × IC50, determined to inhibit latent TGF-β activation by αvβ1 or αvβ6 in cell-based assays (see Table 1). **P < 0.01 vs DMSO; ****P < 0.0001 vs DMSO. ACTA2: α-smooth muscle actin 2; ALK5i: Activin receptor-like kinase 5 inhibitor; COL1A1: Collagen type I alpha I; COL1A2: Collagen type I alpha II; COL3A1: Collagen type III alpha I; Cpd A: Compound A; CTGF: Connective tissue growth factor; DMSO: Dimethyl sulfoxide; GUSB: Glucuronidase β; IC50: 50% inhibitory concentration; HPRT1: Hypoxanthine phosphoribosyltransferase 1; IPF: Idiopathic pulmonary fibrosis; ITGB6: Integrin subunit β 6; MMP1: Matrix metalloproteinase 1; MMP2: Matrix metalloproteinase 2; MMP7: Matrix metalloproteinase 7; mRNA: Messenger ribonucleic acid; PCLS: Precision-cut lung slice; RPLP0: Ribosomal lateral stalk subunit P0; SD: Standard deviation; SERPINE1: Serpin family E member 1; SNAI1: Snail family transcriptional repressor 1; TGF-β: Transforming growth factor-β; TIMP1: Tissue inhibitor of metalloproteinase 1CC BY · PubMed Central
Fig. 2 Effect of selective αvβ6 or αvβ1, dual αvβ6/αvβ1, or multi-αv inhibition on Col1a1 expression in A PCLSs generated from chronic bleomycin-challenged mouse lungs and B PCLSs generated from acute bleomycin-challenged mouse lungs. A Compound A (αvβ1-selective inhibitor) = 471 nM; 3G9 (αvβ6-selective inhibitor) = 0.5 µg/ml; PLN-74809 (dual αvβ6/αvβ1 inhibitor) = 1.82 µM; ALK5i (R 268,712) = 1 µM. Data are mean (± SD) of a single slice from n = 6 mouse lungs. Symbols represent results for individual animals. Culture and treatment were for 7 days. Treatment effects were normalized to average DMSO control. Concentrations selected for integrin inhibitors were ≥ 10 × IC50 determined to inhibit latent TGF-β activation by αvβ1 or αvβ6 (see Table 1). B 3G9 (αvβ6-selective inhibitor) = 1 µg/ml; PLN-74809 (dual αvβ6/αvβ1 inhibitor) = 200 nM; GSK3008348 (multi-αv inhibitor) and CWHM-12 (multi-αv inhibitor) = 1 µM. Data are mean (± SD) of a single slice from n = 5–6 mouse lungs. Culture and treatment were for 3 days. Treatment effects were normalized to DMSO control. **P < 0.01 vs DMSO; ***P < 0.001 vs DMSO; ****P < 0.0001 vs DMSO. ALK5i: Activin receptor-like kinase 5 inhibitor; Col1a1: Collagen type I alpha I; Cpd A: Compound A; DMSO: Dimethyl sulfoxide; IC50: 50% inhibitory concentration; mRNA: Messenger ribonucleic acid; PCLS: Precision-cut lung slice; SD: standard deviation; TGF-β: transforming growth factor-β
Fig. 2 Effect of selective αvβ6 or αvβ1, dual αvβ6/αvβ1, or multi-αv inhibition on Col1a1 expression in A PCLSs generated from chronic bleomycin-challenged mouse lungs and B PCLSs generated from acute bleomycin-challenged mouse lungs. A Compound A (αvβ1-selective inhibitor) = 471 nM; 3G9 (αvβ6-selective inhibitor) = 0.5 µg/ml; PLN-74809 (dual αvβ6/αvβ1 inhibitor) = 1.82 µM; ALK5i (R 268,712) = 1 µM. Data are mean (± SD) of a single slice from n = 6 mouse lungs. Symbols represent results for individual animals. Culture and treatment were for 7 days. Treatment effects were normalized to average DMSO control. Concentrations selected for integrin inhibitors were ≥ 10 × IC50 determined to inhibit latent TGF-β activation by αvβ1 or αvβ6 (see Table 1). B 3G9 (αvβ6-selective inhibitor) = 1 µg/ml; PLN-74809 (dual αvβ6/αvβ1 inhibitor) = 200 nM; GSK3008348 (multi-αv inhibitor) and CWHM-12 (multi-αv inhibitor) = 1 µM. Data are mean (± SD) of a single slice from n = 5–6 mouse lungs. Culture and treatment were for 3 days. Treatment effects were normalized to DMSO control. **P < 0.01 vs DMSO; ***P < 0.001 vs DMSO; ****P < 0.0001 vs DMSO. ALK5i: Activin receptor-like kinase 5 inhibitor; Col1a1: Collagen type I alpha I; Cpd A: Compound A; DMSO: Dimethyl sulfoxide; IC50: 50% inhibitory concentration; mRNA: Messenger ribonucleic acid; PCLS: Precision-cut lung slice; SD: standard deviation; TGF-β: transforming growth factor-βCC BY · PubMed Central
Fig. 3 Mean (± SD) αvβ1 protein levels measured in A lung tissue from healthy subjects vs patients with IPF and B healthy vs fibrotic mouse lung tissue (21 days post-bleomycin challenge). Efficacy of integrin inhibitors of αvβ6 (3G9), αvβ1 (Compound A), or αvβ6/αvβ1 (PLN-74809) at blocking (C) normal human bronchial epithelial cell, D normal human lung fibroblast, and E IPF lung fibroblast adhesion to TGF-β LAP as determined by cell impedance assay. One representative donor cell plotted in (C–E) (mean [± SD] for n = 3 replicate measurements). Pan-αv integrin- and pan-β1 integrin-inhibiting antibodies were also used to demonstrate αvβ1-mediated adhesion of normal and IPF lung fibroblasts to LAP (D, E). Ab: antibody; conc: concentration; Cpd A: Compound A; IPF: idiopathic pulmonary fibrosis; LAP: latency-associated peptide; SD: standard deviation; SMi: small-molecule inhibitor; TGF-β: transforming growth factor-β
Fig. 3 Mean (± SD) αvβ1 protein levels measured in A lung tissue from healthy subjects vs patients with IPF and B healthy vs fibrotic mouse lung tissue (21 days post-bleomycin challenge). Efficacy of integrin inhibitors of αvβ6 (3G9), αvβ1 (Compound A), or αvβ6/αvβ1 (PLN-74809) at blocking (C) normal human bronchial epithelial cell, D normal human lung fibroblast, and E IPF lung fibroblast adhesion to TGF-β LAP as determined by cell impedance assay. One representative donor cell plotted in (C–E) (mean [± SD] for n = 3 replicate measurements). Pan-αv integrin- and pan-β1 integrin-inhibiting antibodies were also used to demonstrate αvβ1-mediated adhesion of normal and IPF lung fibroblasts to LAP (D, E). Ab: antibody; conc: concentration; Cpd A: Compound A; IPF: idiopathic pulmonary fibrosis; LAP: latency-associated peptide; SD: standard deviation; SMi: small-molecule inhibitor; TGF-β: transforming growth factor-βCC BY · PubMed Central
Fig. 4 Pulmonary collagen deposition and Smad3 phosphorylation in bleomycin-challenged mice receiving dual αvβ6/αvβ1 inhibitor. A SHG microscopy images of interstitial collagen deposition (blue) in lung tissue sections collected from sham-challenged or bleomycin-challenged mice (vehicle or 500 mg/kg PLN-74809). B Morphometric analysis of interstitial fibrillar collagen deposition from SHG imaging, and C pSmad3/Smad3 ratio in lung tissue from bleomycin-challenged mice treated with PLN-74809 (100, 250, and 500 mg/kg) or vehicle was compared to sham-challenged mice. PLN-74809 was dosed orally (100–500 mg/kg BID) in mice from 7 to 21 days post-bleomycin-induced lung injury. A Representative images show both fibrotic interstitial fine collagen fibers (blue) and denser normal structural collagens surrounding airways (red). B, C Data presented as box and whisker plot with minimum, 25th, 50th, 75th percentile, and maximum values indicated. *P < 0.05; **P < 0.01; ****P < 0.0001. BID: twice daily; Bleo: bleomycin; PBS: phosphate-buffered saline; pSmad3: phosphorylated Smad3; SHG: second harmonic generation
Fig. 4 Pulmonary collagen deposition and Smad3 phosphorylation in bleomycin-challenged mice receiving dual αvβ6/αvβ1 inhibitor. A SHG microscopy images of interstitial collagen deposition (blue) in lung tissue sections collected from sham-challenged or bleomycin-challenged mice (vehicle or 500 mg/kg PLN-74809). B Morphometric analysis of interstitial fibrillar collagen deposition from SHG imaging, and C pSmad3/Smad3 ratio in lung tissue from bleomycin-challenged mice treated with PLN-74809 (100, 250, and 500 mg/kg) or vehicle was compared to sham-challenged mice. PLN-74809 was dosed orally (100–500 mg/kg BID) in mice from 7 to 21 days post-bleomycin-induced lung injury. A Representative images show both fibrotic interstitial fine collagen fibers (blue) and denser normal structural collagens surrounding airways (red). B, C Data presented as box and whisker plot with minimum, 25th, 50th, 75th percentile, and maximum values indicated. *P < 0.05; **P < 0.01; ****P < 0.0001. BID: twice daily; Bleo: bleomycin; PBS: phosphate-buffered saline; pSmad3: phosphorylated Smad3; SHG: second harmonic generationCC BY · PubMed Central
Fig. 5 Comparison of plasma PLN-74809 concentrations (red) with pSmad3/Smad3 ratio (blue) in A BAL cells and B lung tissue from bleomycin-challenged mice. C Comparison of plasma PLN-74809 concentrations and pSmad2/Smad2 ratio in BAL cells from healthy mice. D Comparison of plasma PLN-74809 concentrations and pSmad3/Smad3 ratio in lung tissue from healthy mice. Bleomycin-challenged mice received three oral, 250 mg/kg doses BID starting 13 days post-challenge, with lung tissue and BAL cells collected 14 days post-challenge at 2, 4, 8, and 16 h post-dose (n = 2 per group). Healthy mice received continuous infusion of PLN-74809 (1, 3, 10, 30, or 100 mg/kg/day) via osmotic minipump. BAL: Bronchoalveolar lavage; BID: twice daily; conc: concentration; PD: pharmacodynamics; PK: pharmacokinetics; pSmad2: phosphorylated Smad2; pSmad3: phosphorylated Smad3; TGF-β: transforming growth factor-β
Fig. 5 Comparison of plasma PLN-74809 concentrations (red) with pSmad3/Smad3 ratio (blue) in A BAL cells and B lung tissue from bleomycin-challenged mice. C Comparison of plasma PLN-74809 concentrations and pSmad2/Smad2 ratio in BAL cells from healthy mice. D Comparison of plasma PLN-74809 concentrations and pSmad3/Smad3 ratio in lung tissue from healthy mice. Bleomycin-challenged mice received three oral, 250 mg/kg doses BID starting 13 days post-challenge, with lung tissue and BAL cells collected 14 days post-challenge at 2, 4, 8, and 16 h post-dose (n = 2 per group). Healthy mice received continuous infusion of PLN-74809 (1, 3, 10, 30, or 100 mg/kg/day) via osmotic minipump. BAL: Bronchoalveolar lavage; BID: twice daily; conc: concentration; PD: pharmacodynamics; PK: pharmacokinetics; pSmad2: phosphorylated Smad2; pSmad3: phosphorylated Smad3; TGF-β: transforming growth factor-βCC BY · PubMed Central
Fig. 6 Effect of dual αvβ6/αvβ1 inhibitor (PLN-74809) and clinical standard-of-care drugs (nintedanib and pirfenidone) on A COL1A1 expression and B fibrosis-related gene expression in PCLSs prepared from explanted lung tissue from patients with IPF, and C Col1a1 expression in PCLSs prepared from chronic bleomycin-challenged mouse lungs. A Data represent mean (± SD) of 5–7 independent IPF tissues with ≥ 3 slices analyzed per patient tissue. Symbols represent results from individual patient tissues. A, B Treatment effects were normalized to DMSO control for each tissue. Culture and treatment were for 7 days. Concentrations used: PLN-74809 = 200 nM; Nin = 75 nM; Pirf = 50 µM; ALK5i (R 268,712) = 1 µM. C Data represent mean (± SD) of a single slice from n = 6 mouse lungs. Symbols represent results for individual slices. Treatment effects were normalized to DMSO control. Culture and treatment were performed for 7 days. *P < 0.05 vs DMSO; **P < 0.01 vs DMSO; ***P < 0.001 vs DMSO; ****P < 0.0001 vs DMSO. ACTA2: α-smooth muscle actin 2; ALK5i: Activin receptor-like kinase 5 inhibitor; IPF: Idiopathic pulmonary fibrosis; COL1A1: Collagen type I alpha I; COL1A2: Collagen type I alpha II; COL3A1: Collagen type III alpha I; CTGF: Connective tissue growth factor; DMSO: dimethyl sulfoxide; GUSB: glucuronidase β; HPRT1: hypoxanthine phosphoribosyltransferase 1; ITGB6: Integrin subunit β 6; MMP1: Matrix metalloproteinase 1; MMP2: Matrix metalloproteinase 2; mRNA: messenger ribonucleic acid; Nin: Nintedanib; PCLS: Precision-cut lung slice; Pirf: pirfenidone; SD: Standard deviation; RPLP0: ribosomal lateral stalk subunit P0; SERPINE1: Serpin family E member 1; SNAI1: Snail family transcriptional repressor 1; TIMP1: tissue inhibitor of metalloproteinase 1
Fig. 6 Effect of dual αvβ6/αvβ1 inhibitor (PLN-74809) and clinical standard-of-care drugs (nintedanib and pirfenidone) on A COL1A1 expression and B fibrosis-related gene expression in PCLSs prepared from explanted lung tissue from patients with IPF, and C Col1a1 expression in PCLSs prepared from chronic bleomycin-challenged mouse lungs. A Data represent mean (± SD) of 5–7 independent IPF tissues with ≥ 3 slices analyzed per patient tissue. Symbols represent results from individual patient tissues. A, B Treatment effects were normalized to DMSO control for each tissue. Culture and treatment were for 7 days. Concentrations used: PLN-74809 = 200 nM; Nin = 75 nM; Pirf = 50 µM; ALK5i (R 268,712) = 1 µM. C Data represent mean (± SD) of a single slice from n = 6 mouse lungs. Symbols represent results for individual slices. Treatment effects were normalized to DMSO control. Culture and treatment were performed for 7 days. *P < 0.05 vs DMSO; **P < 0.01 vs DMSO; ***P < 0.001 vs DMSO; ****P < 0.0001 vs DMSO. ACTA2: α-smooth muscle actin 2; ALK5i: Activin receptor-like kinase 5 inhibitor; IPF: Idiopathic pulmonary fibrosis; COL1A1: Collagen type I alpha I; COL1A2: Collagen type I alpha II; COL3A1: Collagen type III alpha I; CTGF: Connective tissue growth factor; DMSO: dimethyl sulfoxide; GUSB: glucuronidase β; HPRT1: hypoxanthine phosphoribosyltransferase 1; ITGB6: Integrin subunit β 6; MMP1: Matrix metalloproteinase 1; MMP2: Matrix metalloproteinase 2; mRNA: messenger ribonucleic acid; Nin: Nintedanib; PCLS: Precision-cut lung slice; Pirf: pirfenidone; SD: Standard deviation; RPLP0: ribosomal lateral stalk subunit P0; SERPINE1: Serpin family E member 1; SNAI1: Snail family transcriptional repressor 1; TIMP1: tissue inhibitor of metalloproteinase 1CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 94

Metadata

Authors
Decaris, M. L., Schaub, J. R., Chen, C., Cha, J., Lee, G. G., Rexhepaj, M., Ho, S. S., Rao, V., Marlow, M. M., Kotak, P., Budi, E. H., Hooi, L., Wu, J., Fridlib, M., Martin, S. P., Huang, S., Chen, M., Muñoz, M., Hom, T. F., Wolters, P. J., Desai, T. J., Rock, F., Leftheris, K., Morgans, D. J., Lepist, E.-I., Andre, P., Lefebvre, E. A., & Turner, S. M.
Affiliations
  • Pliant (United States) (US)
  • University of California, San Francisco (US)
  • Stanford Medicine (US)
Corresponding author
Turner, Scott M.
Venue
Respiratory Research
Published
2021-10-19
Volume
22
Issue
1
Pages
265-265
ISSN
  • 1465-9921 (ISSN-L)
  • 1465-993X
OpenAlex
W3207714802
Cited by
94
References
53
Citations by year
2026: 16 · 2025: 27 · 2024: 24 · 2023: 21 · 2022: 5 · 2021: 1
FWCI
8.25
Type
journal article
Language
en
Open access
Licence
Locations
  • Respiratory Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
idiopathic pulmonary fibrosis, integrin αvβ6, integrin αvβ1, integrin inhibitors, pulmonary fibrosis, TGF-beta signaling, Smad3 phosphorylation, type I collagen, bleomycin-induced lung fibrosis, nintedanib, pirfenidone, precision-cut lung slices, antifibrotic therapy
MeSH terms
Antifibrotic Agents, Collagen Type I, alpha 1 Chain, Animals, Bleomycin, Cell Line, Disease Models, Animal, Epithelial Cells, Fibroblasts, Humans, Lung, Mice, Inbred C57BL, Phosphorylation, Signal Transduction, Coculture Techniques, Receptors, Vitronectin, Integrin alpha6beta1, Mice, Smad3 Protein, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF. https://app.cochat.ai/papers/10.1186/s12931-021-01863-0
The paper
Decaris, M. L., Schaub, J. R., Chen, C., Cha, J., Lee, G. G., Rexhepaj, M., Ho, S. S., Rao, V., Marlow, M. M., Kotak, P., Budi, E. H., Hooi, L., Wu, J., Fridlib, M., Martin, S. P., Huang, S., Chen, M., Muñoz, M., Hom, T. F., . . . Turner, S. M. (2021). Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF. Respiratory Research. https://doi.org/10.1186/s12931-021-01863-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.